scPharmaceuticals (NASDAQ:SCPH) Price Target Lowered to $12.00 at Maxim Group

scPharmaceuticals (NASDAQ:SCPH) had its price target reduced by Maxim Group from $20.00 to $12.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday.

scPharmaceuticals Trading Down 1.0 %

SCPH stock opened at $3.01 on Thursday. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. scPharmaceuticals has a 12-month low of $2.75 and a 12-month high of $5.70. The stock has a market cap of $150.62 million, a price-to-earnings ratio of -1.58 and a beta of 0.40. The business’s 50-day moving average is $3.28 and its 200 day moving average is $3.80.

scPharmaceuticals (NASDAQ:SCPH) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.05. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The company had revenue of $12.15 million for the quarter, compared to analysts’ expectations of $12.08 million. On average, sell-side analysts anticipate that scPharmaceuticals will post -1.53 EPS for the current fiscal year.

Institutional Trading of scPharmaceuticals

Several institutional investors have recently made changes to their positions in SCPH. BNP Paribas Financial Markets raised its position in shares of scPharmaceuticals by 116.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after buying an additional 3,101 shares during the period. Legato Capital Management LLC purchased a new stake in shares of scPharmaceuticals during the 4th quarter valued at approximately $37,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of scPharmaceuticals during the 4th quarter valued at approximately $38,000. Virtu Financial LLC purchased a new stake in shares of scPharmaceuticals during the 3rd quarter valued at approximately $46,000. Finally, ProShare Advisors LLC purchased a new stake in shares of scPharmaceuticals during the 4th quarter valued at approximately $48,000. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.